Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arena Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients who completed the APD334-003 study

Exclusion Criteria:

• Patients who did not complete the APD334-003 study